Leukocyte and platelet-rich fibrin (L-PRF) is a 3-D autogenous biomaterial derived via simple and rapid centrifugation of whole blood patient samples, in the absence of anti-coagulants, bovine thrombin, additives or any gelifying agents. A relatively new "revolutionary" step in second generation platelet concentrate-based therapeutics, clinical effectiveness of L-PRF remains highly-debatable, whether due to preparation protocol variability, limited evidencebased clinical literature and/or inadequate understanding of its biocomponents. This critical review provides an update on the application of L-PRF during oral surgery procedures, in human Randomized and Controlled Clinical Trials only (up to February 2016). Accordingly, autologous L-PRF is often associated with early bone formation and maturation; accelerated soft-tissue healing; and reduced post-surgical pain and discomfort. L-PRF is a simple, malleable and safe biomaterial suitable for use in oral surgery. An innovative tool in Regenerative Dentistry, L-PRF is a strong alternative and possibly cost-effective biomaterial for oral-tissue regeneration. Preparation protocols require revision and standardization. Furthermore, a good analysis of its rheological properties, biocomponents and their bioactive function would enhance the validity, comprehension and therapeutic potential of the reported findings or observations; a step closer towards a new era of "super" dental biomaterials and bioscaffolds.
Introduction
Despite significant improvements, in reconstruction techniques and materials, during last decades, the regeneration of defects remains a challenge [1] . Indeed, current clinical approaches used to reconstruct and heal complex defects, including different bone grafting methods, such as autologous bone grafts, allografts, bone-graft substitutes, distraction osteogenesis, and/or guided bone regeneration, are deemed restricted, on a daily basis. This is often multi-factorial; whether due to limited self-renewal capacity of the defect and/or the limited donor supply, increased morbidity, risk of antigenicity and foreign body reactions, associated with the grafts used. Operativeassociated time and cost contribute as well. Hence, the art and science of oro-maxillo-facial reconstruction is of great interest for contemporary oral and maxillofacial surgeons; in search for better bioengineering strategies and biomaterials: a core driver for biodental research, today [2] .
Briefly, Platelet Concentrates are autologous blood extracts obtained through centrifugation of whole blood samples. The preparation procedure allows the gathering and concentration of platelets and other therapeutic blood constituents (fibrinogen/fibrin, growth factors, leukocytes and circulating cells), in clinically-usable preparations (surgical adjuvants), which may enhance, accelerate and promote tissue (hard and soft) wound healing and regeneration [3] . Despite promising clinical observations, their overall effectiveness remains debated to date. This is mainly due to: mixed/variable clinical outcomes, limited high-quality evidence-based literature, and poor characterization of end-products (and preparation protocols) used in studies; and -until recently -lack of proper terminology systems to classify these preparations [4] . Indeed, the first "classification" consensus [5] was published in 2009, describing 4 different Platelet Concentrate sub-families, based on variability in biological content (fibrin and cell), properties (gelification) and potential applications: pure platelet-rich plasma (P-PRP), leukocyte and platelet-rich plasma (L-PRP), pure plateletrich fibrin (P-PRF) and leukocyte and platelet-rich fibrin (L-PRF) [5] . Today, it can be safely stated that, in oral and maxillofacial surgery, the L-PRF sub-family [4] [5] [6] is receiving the most attention, mainly due to simplicity, user-friendliness and cost-effectiveness, when compared to the PRPs. L-PRF is a second generation autologous platelet concentrate of whole venous blood [4, 6] . A slowly-and strongly-polymerized fibrin gel (Figure 1 ) rich in growth factors, platelets, leukocytes (almost half of the initial blood harvest) and lymphocytes, is collected, following simple and rapid (~10 min) centrifugation (please note that preparation protocols vary- Table 1 ) of blood, in vacutainer tubes, without anti-coagulant. The gathered clot (or biomaterial) is stable, resilient, strong, adhesive and malleable, where it can be cut or adapted into different anatomical defects and applications: used directly as filling material, mixed with bone grating material, or compressed into a strong fibrin membrane. Alongside this established clinical ease of use and handling, the biochemical composition of the L-PRF by-products provides it with attractive hemostatic, angiogenic, osteogenic, anti-inflammatory, anti-microbial, pain-inhibitory and wound healing characteristics [3, 7, 8] . This critical review aims to provide the clinical reader with an up-to-date evidence-based presentation on the evaluation of L-PRF use and application for oro-maxillo-facial tissue regeneration, from high-quality Randomized and Controlled Clinical Trials. Thus, in vitro, in vivo and case report studies were excluded from analysis.
Materials and methods
A structured literature search (Figure 2 ) was performed on PUBMED (October 2015-February 2016) using MESH terms "Platelet-rich fibrin" and "Platelet-rich plasma" according to the Table 2) . Five articles were excluded due to quality/availability lack of randomization. Due to the high heterogeneity, results are presented in a narrative format.
Results and discussion

L-PRF in the treatment of periodontal intrabony defects (IBDs)
Periodontal tissue regeneration has been defined as the formation of new cementum, alveolar bone, and a functional periodontal ligament on a previously-diseased tooth-supporting root surface. Due to limited intrinsic regenerative potential, IBDs are a common and challenging sequel of periodontal disease. Meta-analyses demonstrated that, treatment with conservative open flap debridement, produces an Average Clinical Attachment (CAL) gain of 2.0 mm [9] . While about 1.5 mm may be attributed to newly formed bone; bone-fill does not implicate the regeneration of new attachment to the root [9] . In this context, L-PRF appears promising for regeneration of the whole periodontal attachment system ( Figure 3A and B). Five RCTs addressing the prospective application of L-PRF in the treatment of Periodontal IBD were found. The identified studies allowed for the following comparisons: (a) L-PRF/Open flap surgery vs. Open flap surgery [10] [11] [12] , (b) L-PRF/Bio-Oss® constructs (Bio-Oss®, Geistlich Pharma North America, Inc.) vs. L-PRF [13] and (c) L-PRF/DFDBA constructs vs. DFDBA (Demineralized Freeze-Dried Bone Allograft) [14] . All patients included in those studies were periodontally stable and systemically healthy individuals who presented: similar bilateral IBD of at least 5 mm probing depth, located in vital asymptomatic teeth with no furcation involvement. Studies evaluating the addition of L-PRF to conventional open flap procedure reported the biomaterial notably improving both, clinical and radiographic parameters of IBDs, after 9 [11, 12] and 12 months [10] . A significant increase in probing depth (PD) reduction, CAL gain, post-treatment.
Gingival Margin Stability [(GMS) less post-treatment gingival recession]
, bone defect fill and percentage bone defect fill were noticed in all L-PRF-treated sites vs. controls [10] [11] [12] . Interestingly, higher patient acceptance was also associated with use of L-PRF. Most probably, this is attributed to the accelerated wound healing and pain-inhibitory properties [10, 11] . The presented PD reduction and CAL gain values were superior to previously-reported values in meta-analysis performed for open flap surgery [9] , suggesting the additional benefits of L-PRF over the conventional approach. Treatment with L-PRF/particulate bone-graft substitutes (Bio-Oss® [13] and DFDBA [14] ) provided additional statistically-significant benefits, in terms of PD reduction, CAL gain and bone defect fill vs. graft substitutes, after 6 months. Nonetheless, the absence of "simultaneously-run" L-PRF-alone control renders it difficult to distinguish between the effects of L-PRF and other potential variables in the study. Thus, while promising, additional studies are deemed essential in order to appropriately determine (quantifiably) the effectiveness and advantages of L-PRF application over particulate bonegrafts use.
L-PRF in the treatment of periodontal furcation defects (PFDs)
Molars with furcation involvement (resulting from periodontitis) have higher rates of periodontal breakdown and poorer prognosis, than single-rooted teeth [15] . Contemporary treatment options often include the use of regenerative materials and bone grafts; however, the introduction of L-PRF seems promising for better therapeutic outcomes. In our analyses, 1 RCT addressing the therapeutic use of L-PRF in PFDs was found [16] 66.7% of L-PRF-treated sites. Severity within residual defects was reduced in 5/6 sites (degree I), whereas one defect remained in degree II. Significantly greater PD reduction, CAL gain and radiographic vertical defect fill was reported on experimental sites vs. controls. L-PRF use was also associated with a greater post-treatment GMS [16] .
L-PRF in the treatment of miller class I and II gingival recessions
Gingival recessions are characterized by the apical migration of the gingival margin with subsequent root surface exposure. If left untreated, the condition may lead to other problems including: deficient esthetics, dentine hypersensitivity and higher risk of dental caries [17] . Available treatment options include the use of: (a) Coronally Advanced Flaps (CAF); (b) Connective Tissue Grafts (CTG); and (c) Sub-epithelial Connective Tissue Grafts (SCTG). On their own, the aforementioned techniques have important limitations such as (a) unpredictable long-term root coverage (i.e. CAF decreases from 89% to 58.8% after 6 months), (b) limited gain of keratinized tissue width (KTW); important to prevent recurrence, and (c) adverse post-surgical effects such as pain/discomfort, swelling, flap necrosis, etc. [17] . In this review, five RCTs evaluating the application of L-PRF in the treatment of gingival recessions were identified and included. The studies allowed for the following comparisons: (a) L-PRF/CAF vs. CAF [18] [19] ; (b) L-PRF/CAF vs. EMD (Enamel Matrix Derivate)/CAF [20] ; (c) L-PRF/CAF vs. CTG [21] ; and (d) L-PRF/CAF vs. SCTG [22] . Similar to previous RCTs, all patients included herein were periodontally-stable and systemically healthy; presented with: similar bi-lateral Miller Class I or II gingival recessions (>2 mm depth) localized on vital teeth, without restorations. According to Padma et al., the addition of L-PRF to CAF improved both, clinical outcomes and post-treatment stability of CAF [18] . After 6 months, the authors reported (significantly) more Recession Depth (RD) reduction, CAL gain and KTW increase in all L-PRF-treated sites vs. controls. Interestingly, post-treatment GMS was also higher in the test group with 100% root coverage after 6 months vs. 64.88% in controls [18] . However, in contrary with this RCT, Aroca et al. reported limited clinical benefits when using the L-PRF/ CAF approach [19] . Herein, CAL gain and Gingival Tissue Thickness (GTH) were the only benefiters of the combination; whereas percentage root coverage, full root coverage, GMS and Recession Width (RW) reduction were significantly higher in CAF-alone controls than the test group [19] . Such "contradictory" results may be partially explained by deficient study design, which, not only failed to adequately include blind examiners (leading to potential bias in favor of the "traditional" approach), yet also included: multiple adjacent gingival recessions (with poorer prognosis than single/localized recessions); heavy smokers (in which healing response is usually altered); and the L-PRF were stored in a 4°C refrigerator until use (L-PRF protocols often recommend immediate/fresh use). Indeed, emerging evidence states that growth factor release from L-PRF initiates as early as 5 min from preparation/centrifugation. Hence, storage could have altered its properties and thereby diminished or deteriorated its clinical potential. When compared to other root coverage procedures (EMD/CAF, CTG and SCTG), the L-PRF/ CAF approach showed similar clinical outcomes regarding RD reduction, CAL gain, mean root coverage (%) and complete root coverage (%). KTW increase was the only exception, with both EMD/CAF and CTG controls showing higher KTW than L-PRF-treated groups [20] [21] [22] . Interestingly, all studies reported significantly faster healing and fewer complications (pain and discomfort) when L-PRF was used [20] [21] [22] . Findings are notable, especially when comparing with SCTG (the current "gold standard" technique for treating Miller Class I and II gingival recessions); indicating that L-PRF/CAF could be a safer and less invasive alternative to current grafting techniques, and a more cost-effective strategy or approach than EMD is in treating Miller Class I and II gingival recessions (Figure 3C) .
L-PRF in sinus floor augmentation
Resorption of the upper jaw bone after tooth loss is a frequent problem faced in posterior maxillary implant placement due to lack of sufficient bone mass for anchorage. Common maxillary sinus augmentation techniques provide a solution via increasing the available bone height at the expense of sacrificing volume of the maxillary sinus [23] . Traditionally, autologous bone grafts and resorbable membranes are used to promote osteogenesis and avoid soft tissue in-growth into the surgical site. However, donor site morbidity and size restrictions, latter resorption of the graft and high-cost of membranes, are main disadvantages [24, 25] . In this context, L-PRF appears to provide a promising alternative overcoming such limitations. In this review, two RCTs evaluating the use of L-PRF in lateral window sinus augmentation were found. Applications were performed either as: (a) grafting material (L-PRF/Bio-Oss® constructs vs. Bio-Oss®) [26] or (b) absorbable covering membrane for the lateral osteotomy window (L-PRF vs. Geistlich Bio-Gide®) [27] . In both studies, included subjects were systemically healthy adults with maxillary atrophy (defined as <5 mm residual bone crest height measured in OPG/orthopantomogram). Smoking status was not assessed. The addition of L-PRF to Bio-Oss® bone-substitute revealed neither advantages nor disadvantages over Bio-Oss®-alone controls [26] . After 6 months, clinical and radiographic examinations revealed both groups exhibiting similar amounts and density of mineralized tissues, with no signs of material resorption. Histological evaluations also showed non-significant differences regarding: (a) percentage of newly formed bone, (b) percentage of residual Bio-Oss®, (c) bone-to-bonesubstitute contact, and (d) post-treatment inflammatory reactions [26] . Regarding coverage of lateral osteotomy sinus window, L-PRF use resulted in a similar amount of vital bone formation (%) and residual bone-substitute when compared to Bio-Gide® controls (L-PRF: 17.0 and 15.9%, Bio-Gide®: 17.2 and 17.3%, differences are not statistically-significant). Overall, despite a slightly superior to no coverage at all (12.1%), it can be stated that results were similar to those reported using other conventional membranes (collagen: 17.6%; e-PTFE: 16.9%) [27] . Within the presented limitations in both RCTs, evidence suggests that L-PRF is a safe, simple to use and handle, and cost-effective alternative to traditional bone grafts and absorbable membranes; in low-income patients, pursuing maxillary sinus augmentation procedures.
L-PRF in alveolar ridge preservation
Post-extraction changes in alveolar bone compromise prosthodontic rehabilitation with fixed, removable and/or implant-supported prosthesis. Alveolar Ridge Preservation (ARP) is a technique which involves the use of grafting and barrier materials in order to significantly reduce post-extraction bone loss [28] . L-PRF has been demonstrated to accelerate/enhance bone repair [29, 30] , promote fibroblast proliferation [3, 30] and increase vascularity [31] ; thereby potentially favoring the post-extraction healing process and the ARP approach. Yet, a single RCT evaluating the use of L-PRF in ARP was identified, according to the inclusion criteria set herein [32] . This sole study compared the application of L-PRF vs. natural blood clots in post-extraction sockets of third molars. Patients were systemically healthy and non-smoking adults requiring bi-lateral mandibular third molar removal. The use of L-PRF significantly improved post-extraction soft tissue healing after 7 days [32] . Early and significantly-higher radiographic bone formation/maturation was noticed in the L-PRF treated sites vs. controls, at 8 weeks. By 12 weeks, inter-group differences were non-significant. Radiographic bone density (measured by gray scale value) at 12 weeks increased in the biomaterial group compared to controls, nonetheless, the differences were not significant [32] . Similar to other studies, L-PRF reduced early post-surgical pain (VAS scale) on day 1; however inter-group differences were not significant by day 7 [32] .
Personal expertise: L-PRF in periodontally accelerated osteogenic orthodontics
In our own pilot prospective observational study [30] involving a cohort of 11 patients (with informed consent) receiving a Wilcko's modified PAOO (Periodontally Accelerated Osteogenic Orthodontics-a somewhat new surgical procedure which allows faster tooth movement via combining orthodontic forces with corticotomy and grafting of alveolar bone plates) technique with L-PRF (incorporated into the graft and as covering membrane), accelerated wound healing with no signs of infection or adverse reactions was evident ( Figure 3D) . Post-surgical pain, inflammation and infection were recorded for 10 days post-operatively, while the overall orthodontic treatment and post-treatment stability were followed up to 2 years. In our data analysis, post-surgical pain was found to be either "mild" (45.5%) or "moderate" (54.5%); immediate post-surgical inflammation was recorded as either "mild" (89.9%) or "moderate" (9.1%); and, resolution was marked to begin on day 4 where most patients experienced either "mild" or no inflammation (72.7 and 9.1%, respectively). Interestingly, complete resolution was achieved in all patients by day 8, the average orthodontic treatment time was calculated at 9.3 months and all cases were stable throughout. Thus, we concluded that combining L-PRF with traditional bone grafts (L-PRF plug or block) potentially accelerates wound healing and reduces post-surgical pain, inflammation and infection without interfering with tooth movement and/or post-orthodontic stability, over an extended 2-year observational period; thereby alleviating the need for analgesics and anti-inflammatory medications [30] .
Conclusions and closing remarks
Tissue regeneration and anatomical reconstruction in defects of the oro-maxillo-facial complex have been always a critical and controversial issue. Both, quality and quantity of the regenerated tissues are important to consider, esthetically and functionally. Practically, the surgeon is faced with an ample collection of regenerative techniques and materials to choose from. How can one select the "ideal" or "best-fit" strategy and procedure for an optimal clinical outcome? Evidence-based studies? Level of evidence? To the best of our knowledge, this is the first review of Randomized Controlled Clinical Trials on L-PRF use and application in Oral Surgery. While the available literature is found to be highly-limited, L-PRF can be indicated as an innovative tool for contemporary oro-maxillo-facial tissue regeneration and bioengineering. Indeed, existing evidence suggests that L-PRF improves early wound healing and promotes post-surgical bone formation/maturation. However, it is noteworthy that a clearer consensus seems to be present regarding its significant beneficial impact on post-surgical pain and discomfort control, regardless the type of procedure. Unlike its predecessors, new L-PRF preparations tend to function more as biologically-active biomaterials and scaffolds for the delivery of autologous cells, cytokines and growth factors.
Thus, L-PRF should be considered a "living tissue" preparation for natural guided tissue regeneration and not simply a "growth factor-rich" surgical adjuvant. Yet, it is safe to say that this remains an un-explored territory in Dental Biomaterial (Dental Bioengineering) Research, in general.
Our group is currently investigating the potential of incorporating oral-derived mesenchymal stem cells or growth-factor embedded nanoparticles within the L-PRF, as "super" or "smart" bio-scaffolds, to further boost, with predictability, bone formation, soft tissue healing, treatment time and post-surgical stability, in advanced oro-maxillo-facial surgical procedures such as Periodontally-Accelerated Osteogenic Orthodontics.
Our research extends to investigate the potential of L-PRF in reducing the need for prescription drugs following invasive surgical procedures such as third molar extraction and cysts resections.
Finally, we are vigorously working on characterizing the rheological and biological variations of L-PRF, alongside partnering up with nurses, physicians and dentists to standardize the preparation protocol, for use in other therapeutic indications.
